Lupin has disclosed that it has obtained tentative approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Obeticholic Acid Tablets in 5 mg and 10 mg dosages, which is a generic version of Intercept Pharmaceuticals’ Ocaliva Tablets.
As per IQVIA MAT December 2022, in the United States, Obeticholic Acid Tablets (RLD Ocaliva) had an estimated annual sales of USD 255 million.
Obeticholic Acid Tablets are used to treat a certain type of liver disease known as primary biliary cholangitis (PBC) in combination with other medications, or when other treatments have failed.
It works by increasing the flow of bile in the liver, which helps to reduce the number of harmful substances in the liver.
At around AM, Lupin was trading at Rs650.70, 0.33% higher against the previous close of Rs648.55 on NSE. The counter opened at Rs651 and touched intraday high of Rs653.50.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
